Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in active lupus nephritis
NCT05609812Phase 3Withdrawn
- Sponsor
- Vera Therapeutics
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Atacicept with Placebo (2 arms). Primary endpoint: Renal Response at 52 weeks. Planned start Nov 2022; status: withdrawn.
02
Drugs
atacicept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05609812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609812.